Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics Inc. witnessed a 4.0% drop in its stock price in after-hours trading following the announcement of a public offering of its common shares. The company's share price plummeted from $92.72 to $89.00 in response to the news, released shortly after the market closed. This move caused concern among investors, who were apprehensive about potential share dilution resulting from the new equity being introduced to the market without a corresponding clinical breakthrough.

The underwriters have the option to purchase an additional 15% of the shares offered, which could further contribute to the dilution. Spyre intends to allocate the proceeds from the offering towards various programs, including preclinical studies, clinical trials, manufacturing, Phase 3 readiness activities, and advancing its lead asset SPY072 into late-stage development for hidradenitis suppurativa.

The joint book-running managers for the offering are Jefferies, TD Cowen, Leerink Partners, and Stifel, with LifeSci Capital serving as the passive bookrunner. Despite the broader market showing little impact on the decline, the S&P 500, Dow Jones, and Nasdaq remained relatively unchanged. The consensus among analysts remains positive, with a moderate buy rating and an average price target higher than the current trading level.

Although the stock has experienced significant growth from its 52-week low to a high of $110.18, the after-hours decline is primarily driven by the immediate impact of the equity dilution, rather than any deterioration in Spyre's clinical prospects.